Pharmaceutical giant Merck & Co. has dropped a candidate for the treatment of geographic atrophy (GA), narrowing the scope of its long-standing collaboration with NGM Biopharmaceuticals.
Merck lost interest in NGM621, an anti-complement C3 antibody being trialled in patients with GA, after the therapy failed a mid-stage trial in October last year.
Merck lost interest in NGM621… after the therapy failed a mid-stage trial in October last year
Merck had retained an option to license NGM621, its related compounds and potentially other preclinical ophthalmology compounds but the company told NGM verbally that it was no longer interested, according to a document filed with the US Securities and Exchange Commission.
